Patents
Literature
29 results about "Antigen processing" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
'Antigen processing or cytosolic' pathway is an immunological process that prepares antigens for presentation to special cells of the immune system called T lymphocytes. It is considered to be a stage of antigen presentation pathways. This process involves two distinct pathways for processing of antigens from an organism's own (self) proteins or intracellular pathogens (e.g. viruses), or from phagocytosed pathogens (e.g. bacteria); subsequent presentation of these antigens on class I or class II major histocompatibility complex (MHC) molecules is dependent on which pathway is used. Both MHC class I and II are required to bind antigen before they are stably expressed on a cell surface. MHC I antigen presentation typically (considering cross-presentation) involves the endogenous pathway of antigen processing, and MHC II antigen presentation involves the exogenous pathway of antigen processing. Cross-presentation involves parts of the exogenous and the endogenous pathways but ultimately involves the latter portion of the endogenous pathway (e.g. proteolysis of antigens for binding to MHC I molecules).
Engineered immune cells with enhanced potency and uses of same in immunotherapy
PendingUS20260000761A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyNatural Killer Cell Inhibitory ReceptorsAntigen receptors
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors as well as genetically edited or otherwise engineered enhance the persistence the cells in immunotherapy. In several embodiments, the cells are edited to knock out a target gene that encodes a protein involved in antigen processing and presentation by major histocompatibility complex class I molecules. In several embodiments, a mixture of immune cell types is used, optionally in allogeneic therapy. The engineering and editing of the cells, such as NK cells and / or T cells exhibit enhanced cytotoxicity and / or persistence, as well as reduced risk of reduced graft versus host, host versus graft, and graft versus graft effects.
Owner:NKARTA INC
Methods and systems for developing personalized vaccine by identification and prioritization of mutation-derived neoantigens
Cancer immunology provides promising new avenues for cancer treatment but validation of potential neoantigens to target is costly and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency, provides screening method to identify and prioritize candidate neoantigens using sequencing data. Methods of the invention thereby save time and money by identifying the priority candidate neoantigens for further experimental validation.
Owner:PERSONAL GENOME DIAGNOSTICS INC
A recombinant CLEC9A gene and its application in improving the immunity and disease resistance of animals
ActiveCN119661686BCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsAntigenDisease
The present invention relates to the field of animal husbandry technology, and in particular to a recombinant CLEC9A gene and its use in improving the immunity and disease resistance of animals. The recombinant CLEC9A protein comprises the amino acid sequence shown in SEQ ID NO.1; the recombinant CLEC9A gene comprises the nucleotide sequence shown in SEQ ID NO.2; and the use includes: improving the immunity and disease resistance of animals. The present invention modifies the porcine CLEC9A gene to obtain a recombinant CLEC9A gene, which can be expressed normally and, when overexpressed in porcine BMDC cells, can significantly increase the expression of genes related to antigen processing and presentation, while also improving their survival and proliferation ability in an LPS-induced environment. This is of great significance in the field of animal husbandry.
Owner:CHINA AGRI UNIV
Tolerogenic peptides
PendingUS20260034200A1Metabolism disorderPeptide/protein ingredientsAntigen processingPancreatic A Cells
The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.
Owner:THE UNIV OF BIRMINGHAM
Compositions and methods for use in immunotherapy
Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.
Owner:SCRIBE THERAPEUTICS INC
Tolerogenic peptides
PendingCN120225217AMetabolism disorderPeptide/protein ingredientsAntigen processingPancreatic A Cells
The present disclosure is based, in part, on the study of novel tolerogenic peptides derived from proteins expressed by pancreatic cells, which peptides have been developed for use for antigen-specific immunotherapy of type 1 diabetes mellitus. Disclosed are tolerogenic peptides capable of binding class II MHC molecules independent of antigen processing for use in the treatment of Type 1 diabetes wherein the peptides are derived from proteins expressed by pancreatic cells.
Owner:THE UNIV OF BIRMINGHAM
Use of carnosic acid as an erap1 inhibitor for the preparation of a medicament for the treatment of ankylosing spondylitis
The application relates to the field of biotechnology, and particularly relates to the application of carnosic acid as an ERAP1 inhibitor in the preparation of a drug for treating ankylosing spondylitis of an autoimmune disease. The application first discovers that a monomer compound carnosic acid from a natural product source can be used as an ERAP1 direct targeting inhibitor in the preparation of a drug for regulating an endogenous antigen processing and presentation pathway and ankylosing spondylitis of a related autoimmune disease. The carnosic acid can be specifically combined in an ERAP1 active site through direct high-activity targeting, and the carnosic acid inhibits the activity of the ERAP1, is the highest in activity in the world, and has high selectivity in targeting the ERAP1 active site. The carnosic acid reverses the ankylosing spondylitis molecular pathological phenotypes caused by abnormal ERAP1 activity, including endoplasmic reticulum stress, reducing an extra amount of HLA-B27 molecules displayed on a cell surface, reducing the proportion of the HLA-B27 molecules incorrectly assembled on the cell surface, and maintaining normal antigen presentation functions.
Owner:SHENYANG PHARMA UNIV
Tolerogenic peptide
PendingJP2025525009AMetabolism disorderPeptide/protein ingredientsDiabetes TherapyAntigen processing
The present disclosure is based in part on research related to novel tolerogenic peptides derived from proteins expressed by pancreatic cells, developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed are tolerogenic peptides that can bind to MHC class II molecules without relying on antigen processing, and are derived from proteins expressed by pancreatic cells, for use in the treatment of type 1 diabetes.
Owner:THE UNIV OF BIRMINGHAM
Method for predicting immunogenic epitopes and device using the same
The present invention relates to a method for predicting immunogenic epitopes and an apparatus using the same. The method for predicting immunogenic epitopes according to the present invention includes the steps of: calculating the degree of influence of factors involved in a biological process of a tumor cell for an epitope and characteristics of the epitope on the immunogenicity of the epitope; performing at least one of standardization and normalization on the calculated value; and inputting the value after the standardization and normalization into a pre-trained artificial intelligence model to predict the immunogenicity of the epitope. The biological process may include an antigen processing stage, an antigen presentation stage, an immune stage, and a tumor microenvironment, and the factors involved in the tumor microenvironment may be at least one of an inflammatory response, a B-cell linear epitope, and a B-cell conformational epitope.
Owner:INVITES GENOMICS CO LTD
Application of tetrahydrobiopterin in enhancing dendritic cell function and relieving related diseases
The invention discloses an application of tetrahydrobiopterin in enhancing functions of dendritic cells and relieving related diseases, and finds that tetrahydrobiopterin can promote maturation of the dendritic cells, improve antigen processing and presenting capabilities of the dendritic cells and / or enhance T cell activation capability mediated by the dendritic cells for the first time. The tetrahydrobiopterin can promote synergistic activation of vaccine-induced humoral immunity and cellular immunity by enhancing the dendritic cell function, and the invention provides a new thought and strategy for vaccine research and development, and has important scientific significance and clinical application value.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES +1
Compositions and methods for reducing cell therapy immunogenicity
PendingUS20250325585A1Virus peptidesImmunoglobulins against cell receptors/antigens/surface-determinantsAntigen processingTransporter associated with antigen processing
This application provides, in part, methods and compositions for decreasing the immunogenicity of cell therapies (e.g., CAR-T cell therapies) using inhibitors of transporter associated with antigen processing (TAPi) and oligonucleotides that decrease the expression of an immunogenic proteins (e.g., MHC Class I and Class II).
Owner:THE GENERAL HOSPITAL CORP
Reagents and methods for treating cancer and autoimmune disease
PendingUS20260146087A1Immunoglobulin superfamilyAntibody mimetics/scaffoldsImmunologic disordersAutoimmune condition
Disclosed herein are methods for treating cancer by administering to a subject having cancer antibodies against one or more of CD300c, BTN5 (Erythroid membrane-associated protein), TAPBPL (antigen processing (TAP) binding protein like protein), Skint8 (selection and upkeep of intraepithelial T cells 8 protein), and CD300f. Also disclosed herein are methods for treating autoimmune diseases by administering to a subject having an autoimmune disease an IgV domain, or a nucleic acid encoding an IgV domain, from one or more of CD300c, BTN5, TAPBPL, Skint8, and CD300f. Also disclosed herein are antibodies against CD300c and TAPBPL, and fusion proteins that can be used in the methods for treating autoimmune disease.
Owner:UNIV OF CONNECTICUT
Application of engineering modification of macrophages by using SPARC protein to activate immune function
The invention relates to application of engineering modification of macrophages by using SPARC protein to activate an immune function, and belongs to the technical field of biological medicines. The SPARC protein is overexpressed in the macrophage or the endogenous expression of the SPARC protein is enhanced through a genetic engineering means, so that the polarization of the macrophage to a pro-inflammatory M1 type is remarkably promoted, specifically, the secretion amount of TNF-alpha is increased, the positive rate of HLA-C surface expression is increased, and an M2 type transformation marker CD206 is effectively inhibited. According to the present invention, the SPARC expression element is innovatively integrated into the chimeric antigen receptor macrophage (CAR-Macrophage) system; in-vivo experiments prove that the engineered cell can improve the tumor volume inhibition rate, and the action mechanism of the engineered cell relates to SHARPIN-mediated NF-kappa B pathway continuous activation) and PSMB10-driven antigen processing capacity improvement. The invention provides a novel cell drug development scheme with targeting specificity and immune activation efficacy for solid tumor immunotherapy.
Owner:THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN
Active small molecule with biological orthogonal group and application thereof
PendingCN121974910APrecise and specific immune killingHighly efficient specific immune killingOrganic chemistryAntineoplastic agentsTumor targetAntiendomysial antibodies
The invention discloses an active small molecule with a biological orthogonal group and application of the active small molecule, and belongs to the technical field of biological medicine. The active small molecule is a small molecule hapten aiming at KRAS G12C mutant protein and is formed by sequentially covalently connecting a tumor targeting molecule (AMG510), a PEG Linker and a biological orthogonal group (DBCO), and the PEG chain length is 4, 10 or 16; the small-molecule hapten can be specifically combined with KRAS G12C protein inside and outside cells, after antigen processing, the small-molecule hapten is presented to the surfaces of tumor cells by MHC-I molecules to form an artificial new antigen, the artificial new antigen and an Anti-human-CD3-N3 antibody carrying an azide group are subjected to a biological orthogonal reaction, T cells are recruited and activated in situ, and accurate and efficient killing of the KRAS G12C mutant tumor cells is achieved.
Owner:CHONGQING MEDICAL UNIVERSITY
Neoantigen analysis
Cancer immunology provides a desirable new approach for cancer treatment, but verifies that the potential neoantigens to be directed against targets are cost-effective and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency provides screening methods for identifying and prioritizing candidate neoantigens using sequencing data. The methods of the invention save time and money by identifying preferential candidate neoantigens for further experimental verification.
Owner:PERSONAL GENOME DIAGNOSTICS INC
Methods of screening for peptide-HLA class i alloreactivity
PendingUS20250362287A1Immunoglobulin superfamilyMicrobiological testing/measurementAntigen processingImmunotherapeutic agent
Provided herein is a recombinant cell comprising a deletion of a gene encoding a transporter associated with antigen processing (TAP) protein and mutations in the CD3 epsilon gene and an HLA-A gene. Also provided are systems and methods for screening for alloreactivity and specificity of an immunotherapeutic agent, such as a bispecific T cell engager or an engineered T cell receptor (TCR).
Owner:AMGEN INC
Materials and methods for assessing antigen presentation mechanism components and uses thereof
PendingCN120359417AMicrobiological testing/measurementImmunoglobulins against animals/humansAntigen processingImmunotherapeutic agent
Disclosed herein are compositions, systems, and methods for identifying subjects likely to be responsive to MHC-I dependent immunotherapeutic agents based on expression of components of the antigen presentation mechanism, and particularly expression of constituent elements of the antigen processing related transporter complex and major histocompatibility complex class I.
Owner:VENTANA MEDICAL SYSTEMS INC
Tolerogenic peptides
PCT designated stageWO2026003516A1Allergen ingredientsAnimals/human peptidesAntigen processingAllergy prevention
The invention relates to a tolerogenic polypeptide capable of binding to an MHC Class II molecule independent of antigen processing, which is derived from Der p 1, and its uses in the treatment or prevention of an allergy. The invention also relates to method of treating or preventing an allergy in a subject in need thereof, comprising administering to the subject a therapeutically affective amount of the tolerogenic polypeptide.
Owner:THE UNIV OF BIRMINGHAM
Mutants of ligand dependent corepressor (LCOR) and uses thereof
The present invention provides a new and improved cancer therapy based on an isolated or synthetic polynucleotide sequence encoding a mutant of a ligand-dependent corepressor (LCOR), or a fragment thereof, capable of inducing expression of an antigen processing / presentation mechanism (APM) gene, wherein the mutant or fragment of the ligand-dependent corepressor (LCOR) is characterized by comprising a functional HHT domain, and wherein the mutant or fragment of the ligand-dependent corepressor (LCOR) is further characterized by a deletion or inactivation of a nuclear receptor binding domain.
Owner:MEDICAL RES HOSPITAL INST FOUNDATION
Materials and methods for assessing components of the antigen presentation machinery and their uses
PendingJP2026502116AMicrobiological testing/measurementBiological material analysisAntigen processingImmunotherapeutic agent
Disclosed herein are compositions, systems, and methods for identifying subjects who may be responsive to MHC-I-dependent immunotherapeutic agents based on the expression of components of the antigen presentation machinery, particularly the expression of components of the antigen processing-associated transporter complex and major histocompatibility complex class I.
Owner:VENTANA MEDICAL SYSTEMS INC
Systems and methods for MHC class II epitope prediction
ActiveUS12374423B2Bacterial antigen ingredientsAntibacterial agentsImmunodominant EpitopesAntigen processing
A system and method for prediction of immunodominant epitopes is provided herein. MHCII peptidomics was used to discover complex bacterial epitopes and host antigen processing pathways. Novel insights into the features of antigenicity are leveraged to build an algorithm for prediction of immunodominant epitopes. Use of immunodominant epitopes is described.
Owner:THE GENERAL HOSPITAL CORP +1
Ligand-dependent corepressor, (LCOR), mutants and fragments thereof, and uses for cancer therapy
PCT designated stageWO2026057875A1Peptide/protein ingredientsReceptors for hormonesAntigen processingLCOR
The present invention provides a novel and improved cancer therapy based on an isolated or synthesized polynucleotide sequence coding for a mutant of a Ligand-dependent corepressor (LCOR), or a fragment thereof, capable of inducing expression of the antigen processing / presentation machinery (APM) genes, wherein the mutant or fragment of a Ligand-dependent corepressor (LCOR) is characterized by comprising a functional HTH domain, and wherein said mutant or fragment of a Ligand-dependent corepressor (LCOR) is further characterized by comprising an absent or inactivated Nuclear Receptor Binding Domain.
Owner:MEDICAL RES HOSPITAL INST FOUNDATION
Gp96 tumor neoantigen prediction method and application
The application discloses a gp96 tumor neoantigen prediction method and application thereof, and relates to the technical field of tumor neoantigen prediction. The method comprises the following steps: S1, isolation and purification of gp96-tumor polypeptide complexes; S2, dissociation and purification of polypeptides; S3, mass spectrometric identification and sequence analysis of mutant peptides; S4, MHC affinity prediction; and S5, immunogenicity verification. The application takes gp96 as a natural biological concentrator, the captured polypeptides include products in a natural antigen processing path of tumor cells, and antigen peptide segments with potential immunological significance are enriched. In combination with MHC affinity prediction and immunogenicity function verification, the true positive rate of neoantigen screening is significantly improved. In a verification experiment on colon cancer samples, among 7 candidate neoantigens obtained through prediction, 4 can significantly activate autologous T cells of a patient to secrete IFN-gamma, and show a high immunogenicity verification positive rate.
Owner:SHENZHEN KANGERNUO BIOTECHNOLOGY CO LTD
Compositions and methods for degradation-enhanced immunotherapies
PCT designated stageWO2026080609A1Antibody mimetics/scaffoldsPeptide/protein ingredientsAntigen processingAntigen binding
The present disclosure relates to compositions and methods for inducing an immune response using a degradation-enhanced composition. In particular, the compositions comprise a degradation-enhanced immunogenic construct comprising: (a) an antigen, (b) a ligand that binds a degradation-enhancing target molecule, and (c) a linker connecting the antigen and the ligand, wherein the composition enhances antigen processing, presentation, and immune activation, thereby improving adaptive immune responses.
Owner:VIRGINIA COMMONWEALTH UNIV
An antigen filtration device
This invention provides an antigen filtration device, belonging to the technical field of antigen processing equipment. The antigen filtration device includes a body, a filtration unit, a lifting device, and a reciprocating device. The body includes a shell divided into an upper cavity and a lower cavity by a circular slide rail, with a turntable slidably connected within the circular slide rail. The filtration unit is located in the upper cavity and includes an upper tube, a lower tube, and an ultrafiltration membrane disposed within both tubes. The lifting device includes at least two support parts and a lifting part. The flange of the upper tube can be placed in an adapter groove, and the upper and lower tubes are fixed together by washers and bolts. This not only facilitates the disassembly of the upper and lower tubes but also enhances their sealing. Furthermore, the upper and lower tubes form an integrated structure, allowing for rapid secondary filtration after primary filtration, thereby improving filtration efficiency.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD
Method for predicting immunogenic epitopes and device using same
The present invention relates to a method for predicting an immunogenic epitope and a device using the same. The method for predicting the immunogenic epitopes comprises the following steps: calculating the degrees of influence of factors related to the biological process of the epitopes of tumor cells and the characteristics of the epitopes on the immunogenicity of the epitopes; at least one of normalizing and normalizing the calculated value; and predicting the immunogenicity of the epitope by inputting a value from which at least one of the standardizing and normalizing has been performed into a pre-learned artificial intelligence model, the biological process being composed of an antigen treatment stage, an antigen presentation stage, an immunization stage, and a tumor microenvironment, the factors related to the tumor microenvironment can be at least one of inflammatory response, B cell linear epitope and B cell conformational epitope.
Owner:INVITES GENOMICS CO LTD +1
Methods and systems for identification and prioritization of mutation-derived neoantigens
Cancer immunology provides promising new avenues for cancer treatment but validation of potential neoantigens to target is costly and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency, provides screening method to identify and prioritize candidate neoantigens using sequencing data. Methods of the invention thereby save time and money by identifying the priority candidate neoantigens for further experimental validation.
Owner:PERSONAL GENOME DIAGNOSTICS INC +1
Atlas inference analysis system for cell antigen treatment defects
The invention discloses an atlas inference analysis system for cell antigen treatment defects, relates to the technical field of knowledge atlas inference, and is used for solving the problem of slow explaining and positioning of defect presentation. According to the method, a detection likelihood set is constructed by fusing HLA typing, somatic cell variation, transcriptional expression, immunopeptidomics and surface HLA detection, direct presentation and cross presentation sub-graphs are assembled by adopting a mode gating and loading complex integrity rule, a reachable path and observation consistency matrix is generated, structural contradictions and detection limitations are distinguished, and a detection result is obtained. According to constraint propagation, node cutting and link shrinkage are performed to form an individualized map, defect nodes and defect paths are searched and output based on a minimum interpretation path and a cause and effect graph cost, and a verification and intervention list and clinical decision support output are generated, so that unnecessary detection and intervention attempts are reduced, and the detection efficiency is improved. And the timeliness and consistency of case analysis and strategy making are improved.
Owner:南昌大学第一附属医院
Materials and methods for evaluation of antigen presentation machinery components and uses thereof
PendingUS20260016475A1Microbiological testing/measurementImmunoglobulins against animals/humansAntigen processingImmunotherapeutic agent
Disclosed herein are compositions, systems, and methods for identifying subjects who may be responsive to MHC-I-dependent immunotherapeutic agents based upon the expression of the components of the antigen presentation machinery and, in particular, the expression of the constituent elements of the transporter associated with antigen processing complex and the major histocompatibility complex class I.
Owner:VENTANA MEDICAL SYSTEMS INC